Navegar

Colección

Datos Estadísticas

Artículo

Estamos trabajando para incorporar este artículo al repositorio
Consulte el artículo en la página del editor
Consulte la política de Acceso Abierto del editor

Abstract:

The replication of herpes simplex virus (HSV) type 1 in Vero cells is inhibited in the presence of (22S,23S)-3β-bromo-5α,22,23- trihydroxystigmastan-6-one (6b), a synthetic brassinosteroid derivative. Since a late step of virus multiplication is hindered by 6b, we performed studies of drug-drug combination with acyclovir (ACV) and foscarnet (FOS). It was determined that 6b would act synergistically with low concentrations of ACV and moderate concentrations of FOS against HSV. The best drug combination tested in this study resulted in an increase of 29.3 and 47.2% in antiviral activity for ACV (0.036 μM) and FOS (37.5 μM) in the presence of 14.8 and 6.9 μM of 6b, respectively. Copyright © 2006 S. Karger AG.

Registro:

Documento: Artículo
Título:Synergistic in vitro interactions between (22S,23S)-3β-bromo-5α, 22,23-trihydroxystigmastan-6-one and acyclovir or foscarnet against herpes simplex virus type 1
Autor:Talarico, L.B.; Castilla, V.; Ramirez, J.A.; Galagovsky, L.R.; Wachsman, M.B.
Filiación:Laboratorio de Virología, Departamento de Química Biológica, Universidad de Buenos Aires, Buenos Aires, Argentina
Departamento de Química Orgánica, Facultad de Ciencias Exactas Y Naturales, Universidad de Buenos Aires, Buenos Aires, Argentina
Laboratorio de Virología, Departamento de Química Biológica, Pabellón 2, 1428, Buenos Aires, Argentina
Palabras clave:(22S,23S)-3β-bromo- 5α,22,23-trihydroxystigmastan-6-one; Antiviral drug-drug combinations; Brassinosteroid derivatives; Herpes simplex; 3beta bromo 5alpha,22,23 trihydroxystigmastan 6 one; aciclovir; antivirus agent; foscarnet; unclassified drug; antiviral activity; article; controlled study; DNA sequence; drug activity; drug potentiation; gene frequency; gene mutation; gene targeting; Herpes simplex virus; nonhuman; priority journal; protein phosphorylation; virogenesis; Acyclovir; Animals; Antiviral Agents; Cell Line; Cell Proliferation; Cercopithecus aethiops; Cholestanones; Drug Synergism; Foscarnet; Herpesvirus 1, Human; Molecular Structure
Año:2005
Volumen:52
Número:1
Página de inicio:38
Página de fin:42
DOI: http://dx.doi.org/10.1159/000090242
Título revista:Chemotherapy
Título revista abreviado:Chemotherapy
ISSN:00093157
CODEN:CHTHB
CAS:aciclovir, 59277-89-3; foscarnet, 4428-95-9; (22S,23S)-3beta-bromo-5alpha,22,23-trihydroxystigmastan-6-one; Acyclovir, 59277-89-3; Antiviral Agents; Cholestanones; Foscarnet, 4428-95-9
Registro:https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_00093157_v52_n1_p38_Talarico

Referencias:

  • Oliver, N.M., Collins, P., Van Der Meer, J., Van't Wout, J.W., Biological and biochemical characterization of clinical isolates of herpes simplex virus type 2 resistant to acyclovir (1989) Antimicrob Agents Chemother, 33, pp. 635-640
  • Morfin, F., Thouvenot, D., Herpes simplex virus resistance to antiviral drugs (2003) J Clin Virol, 26, pp. 29-37
  • Edert, D.Y., Finance, C.M.T., Le Faou, A.E., Susceptibility of clinical strains of herpes simplex virus to three nucleoside analogues (2000) Chemotherapy, 46, pp. 195-197
  • Smee, D.F., Bailey, K.W., Morrison, A.C., Sidwell, R.W., Combination treatment of influenza A virus infections in cell culture and in mice with the cyclopentane neuraminidase inhibitor RWJ-2 70201 and ribavirin (2002) Chemotherapy, 48, pp. 88-93
  • Andersen, J.H., Jenssen, H., Gutteberg, T.J., Lactoferrin and lactoferricin inhibit herpes simplex 1 and 2 infection and exhibit synergy when combined with acyclovir (2003) Antiviral Res, 58, pp. 209-215
  • Buckwold, V.E., Implications of finding synergic in vitro drug-drug interactions between interferon-α and ribavirin for the treatment of hepatitis C virus (2004) J Antimicrob Chemother, 53, pp. 413-414
  • Wachsman, M.B., López, E.M.F., Ramírez, J.A., Galagovsky, L.R., Coto, C.E., Antiviral effect of brassinosteroids against herpes virus and arenaviruses (2000) Antiviral Chem Chemother, 11, pp. 71-77
  • Talarico, L.B., Ramírez, J.A., Galagovsky, L.R., Wachsman, M.B., Structure-activity relationship studies in a set of new brassinosteroid derivatives assayed against herpes simplex virus type 1 and 2 in cell cultures (2002) Med Chem Res, 11, pp. 434-444
  • Wachsman, M.B., Ramírez, J.A., Galagovsky, L.R., Coto, C.E., Antiviral activity of brassinosteroids derivatives against measles virus in cell cultures (2002) Antivir Chem Chemother, 13, pp. 61-66
  • Wachsman, M.B., Ramírez, J.A., Talarico, L.B., Galagovsky, L.R., Coto, C.E., Antiviral activity of natural and synthetic brassinosteroids (2004) Curr Med Chem Antiinfect Agents, 3, pp. 163-179
  • Wachsman, M.B., Castilla, V., Talarico, L.B., Ramírez, J.A., Galagovsky, L.R., Coto, C.E., Antiherpetic mode of action of (22S,23S)-3β-bromo-5α,22,23- trihydroxystigmastan-6-one in vitro (2004) Int J Antimicrob Agents, 23, pp. 524-526
  • Field, H.J., Herpes simplex virus antiviral drug resistance - Current trends and future prospects (2001) J Clin Virol, 21, pp. 261-269
  • Shin, J.K., Cai, G.Y., Weinberg, A., Leary, J.J., Levin, M.J., Frequency of acyclovir-resistant herpes simplex virus in clinical specimens and laboratory isolates (2001) J Clin Microbiol, 39, pp. 913-917
  • Chilukuri, S., Rosen, T., Management of acyclovir-resistant herpes simplex virus (2003) Dermatol Clin, 21, pp. 311-320
  • Teme Centurión, O.M., Galagovsky, L.R., Alternative synthesis of 24(S)-homoethylcastasterone from stigmasterol (1998) Anal Asoc Quím Arg, 86, pp. 104-109
  • Denizot, F., Lang, R., Rapid colorimetric assay for cell growth and survival (1986) J Immunol Methods, 89, pp. 271-277
  • Prichard, M.N., Shipman, C., A three-dimensional model to analyze drug-drug interactions (1990) Antiviral Res, 14, pp. 181-206
  • Michelini, F.M., Ramírez, J.A., Berra, A., Galagovsky, L.R., Alché, L.E., In vitro and in vivo antiherpetic activity of three new synthetic brassinosteroid analogues (2004) Steroids, 69, pp. 713-720

Citas:

---------- APA ----------
Talarico, L.B., Castilla, V., Ramirez, J.A., Galagovsky, L.R. & Wachsman, M.B. (2005) . Synergistic in vitro interactions between (22S,23S)-3β-bromo-5α, 22,23-trihydroxystigmastan-6-one and acyclovir or foscarnet against herpes simplex virus type 1. Chemotherapy, 52(1), 38-42.
http://dx.doi.org/10.1159/000090242
---------- CHICAGO ----------
Talarico, L.B., Castilla, V., Ramirez, J.A., Galagovsky, L.R., Wachsman, M.B. "Synergistic in vitro interactions between (22S,23S)-3β-bromo-5α, 22,23-trihydroxystigmastan-6-one and acyclovir or foscarnet against herpes simplex virus type 1" . Chemotherapy 52, no. 1 (2005) : 38-42.
http://dx.doi.org/10.1159/000090242
---------- MLA ----------
Talarico, L.B., Castilla, V., Ramirez, J.A., Galagovsky, L.R., Wachsman, M.B. "Synergistic in vitro interactions between (22S,23S)-3β-bromo-5α, 22,23-trihydroxystigmastan-6-one and acyclovir or foscarnet against herpes simplex virus type 1" . Chemotherapy, vol. 52, no. 1, 2005, pp. 38-42.
http://dx.doi.org/10.1159/000090242
---------- VANCOUVER ----------
Talarico, L.B., Castilla, V., Ramirez, J.A., Galagovsky, L.R., Wachsman, M.B. Synergistic in vitro interactions between (22S,23S)-3β-bromo-5α, 22,23-trihydroxystigmastan-6-one and acyclovir or foscarnet against herpes simplex virus type 1. Chemotherapy. 2005;52(1):38-42.
http://dx.doi.org/10.1159/000090242